

August 05, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Intimation of Schedule of Earnings Conference Call on Q1FY26 Results

Ref.: Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our earlier intimation dated August 01, 2025, regarding a meeting of the Board of Directors of Zota Health Care Limited (the “Company”) is scheduled to be held on August 08, 2025 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that following the announcement of the Unaudited standalone and consolidated Financial Results of the Company for the quarter ended June 30, 2025, the Company will host an Earnings Call on Monday, August 11, 2025 at 04:30 P.M. (IST).

The conference call invitation is enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Zota Healthcare Limited to announce Q1FY26 Results on 8th August 2025; Earnings Call to be held at 4:30 PM IST on 11th August 2025 (Monday)

Surat, 5th August 2025: Zota Health Care Limited, one of the leading pharmaceutical companies with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, will announce financial results for **the First quarter period ended 30th June 2025 on 8th August 2025**. **Following the announcement, the management of the Company will host an Earnings Call on Monday, 11th August 2025 at 4:30 PM (IST).**

The Details of Q1FY26 Earnings Call are:

Date:	Monday, August 11 th , 2025
Time:	16:30 hrs. IST
Duration:	60 minutes
Dial-in Details:	
<i>Participants are encouraged to dial in 10 minutes prior to the call start time to avoid last-minute hold times. If you reach an operator during the dial-in process, please inform them that you would like to join the “Zota Healthcare Limited Q1FY26 Earnings Conference Call”.</i>	
Universal Access numbers	+91 22 6280 1107 +91 22 7115 8008
Pre-Registration Facility	<ul style="list-style-type: none">Step 1: Pre-register here. You will receive an email confirmation with the call details on the registered email address.Step 2: Dial into the call on the Conference Call date, you will be directly connected to the call.

Management Representation from Zota Healthcare Limited

Mr. Himanshu Zota, Founder and Whole-Time Director

Mr. Moxesh Zota, Managing Director

Dr. Sujit Paul, Group Chief Executive Officer

About Zota Health Care Limited:

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 520 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration.

Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: www.zotahealthcare.com

For details please contact:

Mr. Ashvin Variya

CS, Zota Health Care Ltd

E: cszota@zotahealthcare.com

Mr. Siddesh Chawan

Ernst & Young LLP, Investor Relations

E: Siddesh.Chawan@in.ey.com

Mr. Ajit Mishra

Ernst & Young LLP, Investor Relations

E: Ajit.J.Mishra@in.ey.com

***Disclaimer:** Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*